Showing results (91-100 of 154) with videos related to

Sort By:
Pageof 16
Leukemia Research|November 27, 2010
Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimensSamantha L Price, Jeffrey E Lancet, Timothy J George, et al.
Nature Immunology|November 18, 2008
The histone deacetylase HDAC11 regulates the expression of interleukin 10 and immune toleranceAlejandro Villagra, Fengdong Cheng, Hong-Wei Wang, et al.
Molecular Immunology|April 22, 2014
Divergent roles of histone deacetylase 6 (HDAC6) and histone deacetylase 11 (HDAC11) on the transcriptional regulation of IL10 in antigen presenting cellsFengdong Cheng, Maritza Lienlaf, Patricio Perez-Villarroel, et al.
Blood|April 7, 2011
Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinibJorge E Cortes, Andreas Hochhaus, Philipp D le Coutre, et al.
Clinical Lymphoma, Myeloma & Leukemia|February 5, 2019
A Phase II Study to Determine the Safety and Efficacy of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase (IDO) Enzyme INCB024360 in Patients with Myelodysplastic SyndromesRami S Komrokji, Sheng Wei, Adam W Mailloux, et al.
Leukemia Research|June 11, 2016
Results of a phase II study of lenalidomide and rituximab for refractory/relapsed chronic lymphocytic leukemiaJulio C Chavez, Miguel Piris-Villaespesa, Samir Dalia, et al.
Transplantation and Cellular Therapy|March 6, 2023
Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular LymphomaNing Dong, Lucía Rubio Lopes-Garcia, David Viñal, et al.
The American Journal of Cardiology|June 19, 2019
Rates and Risk of Atrial Arrhythmias in Patients Treated With Ibrutinib Compared With Cytotoxic ChemotherapyMichael G Fradley, Matthew Gliksman, Josephine Emole, et al.
Heart (British Cardiac Society)|July 2, 2021
Association between ibrutinib treatment and hypertensionDae Hyun Lee, Fahad Hawk, Kieun Seok, et al.
American Journal of Hematology|October 24, 2012
Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromesRami S Komrokji, Maria Corrales-Yepez, Mohamed A Kharfan-Dabaja, et al.
Pageof 16